Patrick Mauro Investment Advisor INC. Takes $2.74 Million Position in Bristol Myers Squibb Company $BMY

Patrick Mauro Investment Advisor INC. purchased a new position in shares of Bristol Myers Squibb Company (NYSE:BMY) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 47,612 shares of the biopharmaceutical company’s stock, valued at approximately $2,743,000. Bristol Myers Squibb makes up about 1.4% of Patrick Mauro Investment Advisor INC.’s holdings, making the stock its 26th largest position.

Several other large investors have also bought and sold shares of BMY. Swiss RE Ltd. bought a new position in shares of Bristol Myers Squibb in the fourth quarter worth about $25,000. Darwin Wealth Management LLC bought a new stake in shares of Bristol Myers Squibb during the 2nd quarter valued at approximately $25,000. Physician Wealth Advisors Inc. increased its position in Bristol Myers Squibb by 73.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 202 shares in the last quarter. Bayban acquired a new position in Bristol Myers Squibb during the 4th quarter worth approximately $31,000. Finally, EQ Wealth Advisors LLC bought a new position in Bristol Myers Squibb in the 4th quarter valued at approximately $32,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

BMY has been the topic of a number of research reports. Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 27th. JPMorgan Chase & Co. increased their price target on Bristol Myers Squibb from $67.00 to $73.00 and gave the company an “overweight” rating in a research note on Friday, July 31st. BMO Capital Markets reissued a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, July 27th. Guggenheim restated a “buy” rating and set a $75.00 price objective (up from $72.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. Finally, TD Cowen started coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They issued a “buy” rating for the company. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Bristol Myers Squibb currently has a consensus rating of “Moderate Buy” and an average target price of $66.06.

Bristol Myers Squibb Trading Up 2.3%

BMY opened at $67.59 on Thursday. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $68.64. The company’s 50 day moving average price is $60.18 and its two-hundred day moving average price is $59.24. The firm has a market capitalization of $138.06 billion, a price-to-earnings ratio of 14.89, a PEG ratio of 0.17 and a beta of 0.22.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.60 by $0.44. The firm had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The company’s revenue for the quarter was up 5.7% on a year-over-year basis. During the same quarter last year, the firm earned $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, research analysts predict that Bristol Myers Squibb Company will post 6.95 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 3.7%. The ex-dividend date of this dividend was Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 55.51%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.